DOCSLIB.ORG

National Coronavirus Response a ROAD MAP to REOPENING

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
National Coronavirus Response a ROAD MAP to REOPENING National Coronavirus Response A ROAD MAP TO REOPENING Scott Gottlieb, MD Caitlin Rivers, PhD, MPH Mark B. McClellan, MD, PhD Lauren Silvis, JD Crystal Watson, DrPh, MPH MARCH 28, 2020 AMERICAN ENTERPRISE INSTITUTE National Coronavirus Response A ROAD MAP TO REOPENING Scott Gottlieb, MD Caitlin Rivers, PhD, MPH Mark B. McClellan, MD, PhD Lauren Silvis, JD Crystal Watson, DrPh, MPH MARCH 28, 2020 AMERICAN ENTERPRISE INSTITUTE AMERICAN ENTERPRISE INSTITUTE Contents Executive Summary ......................................................................................... 1 Slow the Spread in Phase I ........................................................................................................................1 State-by-State Reopening in Phase II ......................................................................................................2 Establish Immune Protection and Lift Physical Distancing During Phase III ...............................2 Rebuild Our Readiness for the Next Pandemic in Phase IV ...............................................................2 Phase I: Slow the Spread ..................................................................................3 Goals ..............................................................................................................................................................3 Thresholds for Action ................................................................................................................................3 Trigger to Begin to “Slow the Spread” ..................................................................................................3 Trigger to Move to Phase II ....................................................................................................................3 Steps Required in Phase I .........................................................................................................................3 Maintain Physical Distancing ................................................................................................................3 Increase Diagnostic Testing Capacity and Build Data Infrastructure for Rapid Sharing of Results. ... 4 Ensure Functioning of the Health Care System ................................................................................... 4 Increase Supply of Personal Protective Equipment ..............................................................................5 Implement Comprehensive COVID-19 Surveillance Systems .............................................................5 Massively Scale Contact Tracing and Isolation and Quarantine .......................................................5 Offer Voluntary Local Isolation and Quarantine ............................................................................... 6 Encourage the Public to Wear Masks ................................................................................................... 6 Trigger for Moving to Phase II ................................................................................................................ 6 Phase II: Reopen, State by State .........................................................................7 Goals ..............................................................................................................................................................7 AMERICAN ENTERPRISE INSTITUTE Thresholds for Action ................................................................................................................................7 Trigger to Lift Physical Distancing Measures ..................................................................................... 7 AMERICAN ENTERPRISE INSTITUTE i Trigger for Returning to Phase I, “Slow the Spread” ......................................................................... 7 Trigger for Moving to Phase III ............................................................................................................ 8 Steps Required in Phase II ........................................................................................................................ 8 Implement Case-Based Interventions ................................................................................................... 8 Begin to Relax Physical Distancing Measures. ....................................................................................... 8 Special Care for Vulnerable Populations .............................................................................................. 8 Accelerate the Development of Therapeutics ........................................................................................ 8 Identify Those Who Are Immune .......................................................................................................... 9 Trigger for Moving to Phase III ............................................................................................................ 9 Phase III: Establish Protection Then Lift All Restrictions ........................................ 10 Goals ........................................................................................................................................................... 10 Thresholds for Action ............................................................................................................................. 10 Trigger to Begin Manufacturing Scale-Up and Vaccine or Therapeutic Prioritization Planning ....10 Trigger for Switch Toward Mass Vaccination ...................................................................................10 Steps to Take in Phase III ....................................................................................................................... 10 Vaccine or Therapeutic Production .....................................................................................................10 Vaccine or Therapeutic Prioritization—When Supply Is Still Limited. .............................................. 11 Mass Vaccination or Therapeutic Distribution—When Supply Is Abundant ................................. 11 Global Vaccine Scale-Up and Vaccination .......................................................................................... 11 Serological Surveys to Determine Population Immunity................................................................... 11 Phase IV: Reopen, State by State ..................................................................... 12 Develop Vaccines for Novel Viruses in Months, Not Years .............................................................12 Modernize and Fortify the Health Care System .................................................................................12 Establish a National Infectious Disease Forecasting Center ...........................................................12 Governance ...............................................................................................................................................12 Acknowledgments ........................................................................................................................................12 About the Authors .......................................................................................................................................12 ii Executive Summary his report provides a road map for navigating 2) Improvements in state and local health care Tthrough the current COVID-19 pandemic in the system capabilities, public-health infrastructure United States. It outlines specific directions for adapt- for early outbreak identification, case contain- ing our public-health strategy as we limit the epidemic ment, and adequate medical supplies; and spread of COVID-19 and are able to transition to new tools and approaches to prevent further spread of the 3) Therapeutic, prophylactic, and preventive treat- disease. We outline the steps that can be taken as epi- ments and better-informed medical interven- demic transmission is brought under control in dif- tions that give us the tools to protect the most ferent regions. These steps can transition to tools and vulnerable people and help rescue those who approaches that target those with infection rather may become very sick. than mitigation tactics that target entire populations in regions where transmission is widespread and not Our stepwise approach depends on our ability to controlled. We suggest measurable milestones for aggregate and analyze data in real time. To strengthen identifying when we can make these transitions and our public-health surveillance system to account for start reopening America for businesses and families. the unprecedented spread of COVID-19, we need to In each phase, we outline the steps that the federal harness the power of technology and drive additional government, working with the states and public-health resources to our state and local public-health depart- and health care partners, should take to inform the ments, which are on the front lines of case identifica- response. This will take time, but planning for each tion and contact tracing. Finally, we must expand our phase should begin now so the infrastructure is in place investments in pharmaceutical research and develop- when it is time to transition. ment into COVID-19 and promote the rapid deploy- The specific milestones and markers included in the ment of effective diagnostics, therapies, and eventually report for transitioning our responses are judgments a vaccine. based on our current understanding, with the goal of facilitating
Load more

Recommended publications
  • Compendium of the Findings of the OPCAST Pandemic Subgroup 12
    1 A Compendium of the Findings of the Obama PCAST Ad Hoc Subgroup on Pandemic Preparedness and Response December 23, 2020 Introduction A subset of the former members of President Obama’s Council of Advisors on Science and Technology (here OPCAST)—ten individuals who played particularly important roles in producing the six OPCAST reports between 2009 and 2016 that dealt with issues related to pandemic preparedness and response1—came together starting in March of this year to consider how insights from those studies might be combined with more recent research and current observations to develop suggestions about how the U.S. response to the COVID-19 pandemic could be improved. The Subgroup has produced six reports, addressing • the national strategic pandemic-response stockpile (May 20) • the role of contact tracing (June 18) • the role of public health data in controlling the spread of COVID-19 (July 28) • testing for the pathogen (August 18) • recommendations for the coming COVID-19 commission (September 21) • needs for improved epidemiological modeling (September 28) Each report was distributed, upon completion, to selected members of the Trump COVID-19 team and the Biden campaign staff, selected governors and members of Congress, selected public health experts outside government, and the media. The reports have also been posted on the OPCAST team’s website, http://opcast.org, together with a few opinion pieces based on them. In the current volume, we have assembled all six reports in full, preceded by a set of brief summaries. Four of the reports are followed by short updates taking account of developments since the reports first came out.
    [Show full text]
  • Principais Vozes Da Ciência No Twitter
    Principais vozes da ciência no Twitter: Mapeando a conversa de cientistas e especialistas sobre a COVID-19 UMA ANÁLISE DA REDE DE INTERAÇÕES NO TWITTER 1 O Science Pulse é uma ferramenta gratuita de social O Instituto Brasileiro de Pesquisa e Análise de Dados é um listening criada para preencher a lacuna entre jornalistas e centro independente de pesquisa e formação de analistas e cientistas. O objetivo é ajudar jornalistas a encontrar pesquisadores nas áreas de Pesquisa, Opinião Pública e conteúdos científicos que são tendência nas redes sociais e Comunicação Digital. a conhecer novos especialistas. O foco do Instituto é a aplicação e o ensino de técnicas e Com um algoritmo próprio, facilita a descoberta das metodologias de análise de dados com sólida formação publicações com maior popularidade dentro da comunidade científica para atuação no mercado. científica, das principais hashtags utilizadas e de perfis interessantes com menor engajamento. Conheça a nossa formação em Data Intelligence com curso exclusivo sobre Análise de Redes! O projeto foi criado pelo Volt Data Lab, agência do ICFJ Knight Fellow Sérgio Spagnuolo, e conta com apoio institucional da Agência Bori. 2 EXPEDIENTE Pesquisador Responsável Pedro Meirelles Coleta dos dados Science Pulse Tratamento dos dados IBPAD - Instituto Brasileiro de Pesquisa e Análise de Dados COMO CITAR? MEIRELLES, Pedro. Principais vozes da ciência no Twitter: Mapeando a conversa de cientistas e especialistas sobre a COVID-19. Relatório. Instituto Brasileiro de Pesquisa e Análise de Dados (IBPAD): Brasília, 2020. 3 METODOLOGIA A rede de interações foi desenvolvida a partir da base de dados do Science Pulse, que reuniu 213.469 publicações de cientistas, especialistas e organizações da comunidade científica sobre a SOBRE O RELATÓRIO COVID-19 entre junho e outubro de 2020.
    [Show full text]
  • Aspectos Multidisciplinares Que Envolvem Direito, Gestão E Finanças Acerca Da Covid-19
    Coordenadores Alessandro Aveni Gustavo Javier Castro Silva Jonas Rodrigo Gonçalves ASPECTOS MULTIDISCIPLINARES QUE ENVOLVEM DIREITO, GESTÃO E FINANÇAS ACERCA DA COVID-19 1ª edição 2020 Editora Processus Alessandro Aveni, Gustavo Javier Castro Silva e Jonas Rodrigo Gonçalves. Aspectos multidisciplinares que envolvem Direito, gestão e finanças acerca da Covid-19. Coordenadores Alessandro Aveni, Gustavo Javier Castro Silva e Jonas Rodrigo Gonçalves. Diagramador e capista Danilo da Costa. Editor Jonas Rodrigo Gonçalves. Brasília: Editora Processus, 2020. 1ª edição 357 fls. ISBN: 978-65-88715-00-0 1.Covid-19. 2.Direito. 3.Gestão. 4.Finanças. I.Título. CDU 610 EQUIPE EDITORIAL Diretora Geral Prof. Claudine Fernandes de Araújo Diretor Acadêmico Prof. Dr. Gustavo Javier de Castro Silva, Faculdade Processus-DF, Brasil. Editor-CheFe Prof. MSc. Jonas Rodrigo Gonçalves, Faculdade Processus-DF, Brasil. Conselho editorial Prof. Dr. Aloísio Rucheinki, Universidade do Vale do Rio dos Sinos, Brasil. Prof. Dr. Arnaldo Santos Bastos, Universidade Federal de Goiás, Brasil. Profa. Dra. Caroline de Abreu Batista Claro, Universidade de Brasília, Brasil. Profa. Dra. Estefânia Naiara da Silva Lino, Universidade de Rio Verde, Brasil. Prof. Dr. Gustavo Rabay Guerra, Universidade, Federal da Paraíba, Brasil. Prof. Dr. Henrique Smidt Simon, Universidade Euro-Americano, Brasil. Prof. Dr. José Eduardo Souza de Miranda, Universidade de Cantabria, Santander, Espanha. Prof. Dr. Márcio Petrocelli Paixão, Universidade Federal do Rio de Janeiro, Brasil Profa. Msc. Patrícia Spagnollo Parise, Universidade de Rio Verde, Brasil Prof. Dr. Rildo Mourão Ferreira, Universidade de Rio Verde Avaliadores Prof. Dr. Arthur Henrique de Pontes Regis, Universidade de Brasília, Brasil. Prof. Dr. Gustavo Javier Castro Silva, Faculdade Processus-DF, Brasil.
    [Show full text]
  • Federal Funding for Health Security in FY2018
    Health Security Volume 15, Number 4, 2017 ª Mary Ann Liebert, Inc. DOI: 10.1089/hs.2017.0047 Federal Funding for Health Security in FY2018 Crystal Watson, Matthew Watson, and Tara Kirk Sell This article is the latest in an annual series analyzing federal funding for health security programs. It examines proposed funding in the President’s Budget Request for FY2018 and provides updated amounts for FY2017 and actual funding for FY2010 through FY2016. The proposed FY2018 budget for health security–related programs represents a significant decrease in funding from prior years and previous administrations. In total, the President’s proposed FY2018 budget includes $12.45 billion for health security–related programs, an estimated decrease in funding of $1.25 billion, or 9%, from the estimated $13.71 billion in FY2017 and an 11% decrease from the FY2016 actual funding level of $13.99 billion. Most FY2018 health security funding ($6.67 billion, 54%) would go to programs with multiple-hazard and preparedness goals and missions, representing a 14% decrease in this funding compared to FY2017. Radiological and nuclear security programs would receive 20% ($2.48 billion) of all health security funding, a slight decrease of 2% from the prior year. Biosecurity programs would be funded at $1.53 billion (12% of health security funding) in FY2018, a decrease of 6% compared to FY2017. Chemical security programs would represent 3% ($389.7 million) of all health security funding in FY2018, a 9% decrease from the prior year. Finally, 11% of health security funding ($1.39 billion) would be dedicated to pandemic influenza and emerging infectious diseases programs, the only category of funding to see an increase (3%) above FY2017.
    [Show full text]
  • Legal-Graphics' 2-19-21 COVID Timeline
    Number of days Overview: Year 2 of COVID since first sign of virus Nov. 23, 2020 Dec. 3, 2020 Dec. 11, 2020 Dec. 21, 2020 Dec. 30, 2020 Worldwide Worldwide Worldwide Worldwide Worldwide Coronavirus Deaths Coronavirus Deaths Coronavirus Deaths Coronavirus Deaths Coronavirus Deaths Link to Source over 1,400,000 over 1,500,000 over 1,600,000 over 1,700,000 over 1,800,000 Signs of Virus 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 Key Events Nov. 16, 2020 Nov. 18, 2020 Nov. 21, 2020 Nov. 25, 2020 Nov. 27, 2020 Nov. 30, 2020 Dec. 3, 2020 Dec. 6, 2020 Dec. 8, 2020 Dec. 11, 2020 Dec. 14, 2020 Dec. 17, 2020 Dec. 21, 2020 Dec. 22, 2020 Dec. 26, 2020 Dec. 29, 2020 Dec. 31, 2020 Jan. 3, 2021 Good News! Moderna says data FDA allows US cases top Picture of US Demand for live Moderna to request Map showing US UK gears up for Chart of cumulative Pfizer vaccine to be How do the Pfizer Vaccinations reach How the Pfizer Vaccines across Could AZD7442 Map showing How vaccinations Interactive US Map shows its vaccine 1st rapid virus test 12 million ... spread economy is Christmas trees emergency states with the huge vaccination number of deaths OK’d in days - and Moderna US nursing homes and Moderna the world prevent COVID-19 which countries were developed by county showing Legal Matters is more than that gives results 'faster' and 'broader' worrisome skyrockets amid authorization their highest number plan watched by country (by “normal” next fall vaccines work? vaccines compare infection have rolled out so quickly risk for COVID 94% effective at home than ever as virus toll of virus coronavirus vaccine of virus deaths by the world number of days in those exposed? a COVID-19 vaccine inflicts damage since 100 deaths Dec.
    [Show full text]
  • Emerging Leaders in Biosecurity Initiative
    Emerging Leaders in Biosecurity Initiative Class of 2017 A competitive fellowship program created to identify, develop, and provide networking opportunities Yearbook for the next generation of leaders in biosecurity. Emerging Leaders in Biosecurity Initiative Contents Letter: 3 Thomas V. Inglesby, Director; Anita Cicero, Deputy Director, Johns Hopkins Center for Health Security Executive Steering Committee 5 Class of 2017 Fellows 9-35 ELBI 2017 Year in Review 36-37 ELBI Program Staff 41 ELBI Alumni 42 Cover and Inside Cover Photo Overlay: Swine Flu Strain Virus Particles. Col- orized transmission electron micrograph of negatively stained SW31 (swine strain) influenza virus particles. Credit: NIAID Emerging Leaders in Biosecurity Initiative The ELBI Fellowship program is made possible through financial support from the Open Philanthropy Project, under management by the Johns Hopkins Center for Health Security, and with the leadership of the ELBI Executive Steering Committee. For more information, please visit the ELBI website: http://www.centerforhealthsecurity.org/our-work/emergingbioleaders Center for Health Security “Modern conditions make the scenario of a global pandemic more likely. Humans are encroaching on animal environments, raising chances for pathogens to adapt from animals to people. An increasing share of the planet lives in megacities, heightening the likelihood of person-to-person transmission of pathogens. The movement of people and microbes around the globe is more efficient than ever. The recent outbreaks of SARS, MERS, and Ebola are only small glimpses of how quickly a deadly virus can spread.” Tom Inglesby and Benjamin Haas Foreign Affairs November 21, 2017 Middle East Respiratory Syndrome Coronavirus particle envelope proteins immunolabeled with Rabbit HCoV-EMC/2012 primary antibody and Goat an- 1 ti-Rabbit 10 nm gold particles.
    [Show full text]
  • National Covid-19 Testing & Tracing Action Plan
    National Covid-19 Update Report Testing & Tracing Time to Redouble Our Efforts on Action Plan Covid-19 Testing Embargoed until 12:01am EDT, Thursday, July 16, 2020 THE ROCKEFELLER FOUNDATION NATIONAL COVID-19 TESTING & TRACING ACTION PLAN 1 This terrifying tragedy was not and is not inevi- Foreword table. America can function safely, even as we fight Covid-19. Other countries have shown that a better alternative is possible. But as we said in America faces an impending disaster. April – when we first released The Rockefeller Foundation’s National Covid-19 Testing Action The extraordinary scale of the Plan – testing is the only way out of our present disaster, and it will remain the case until a vaccine Covid-19 crisis is evident in the or effective therapeutics are widely available. growing deaths and economic losses When we were barely a month into this pan- the pandemic has wrought in every demic, we brought together scientists, industry, technologists, economists, and Republicans state. Devastated minority and and Democrats alike to formulate an action plan low-income families bore the brunt of to expedite the development of our nation’s widespread testing and tracing system. We those costs. As the virus tore across called for rapidly expanded diagnostic test- ing capacity from 1 million tests per week to 3 the country, it exposed the structural million tests per week by June, and to 30 million inequities that have underpinned tests per week by October. Today we’re at 4.5 million tests per week, but unfortunately it’s and undermined our economy taking far too long to get to 30 million tests per week, and communities that most need them – for decades.
    [Show full text]
  • Mark B. Mcclellan, M.D., Ph.D. Duke University 100 Fuqua Drive Box 90120 Durham N.C
    CURRICULUM VITAE MARK B. MCCLELLAN, M.D., PH.D. DUKE UNIVERSITY 100 FUQUA DRIVE BOX 90120 DURHAM N.C. 27708 EDUCATION: 1993 Ph.D., Economics, Massachusetts Institute of Technology 1992 M.D., Harvard-MIT Division of Health Science and Technology, cum laude 1991 M.P.A., Regulatory Policy, Kennedy School of Government, Harvard University 1985 B.A., English/Biology, University of Texas, Austin, summa cum laude CLINICAL TRAINING: 1996 Diplomate, American Board of Internal Medicine 1993 – 1995 Resident in Internal Medicine, Department of Medicine, Brigham and Women's Hospital EMPLOYMENT: CURRENT POSTION 2015 - Present Director of the Duke-Margolis Center for Health Policy 2015 - Present Robert J. Margolis MD Professor of Business, Medicine and Health Policy 2015 - Present Faculty Member & Sr. Policy Advisor, University of Texas, Austin, Dell Medical School PREVIOUS POSITIONS 2007 – 2015 Senior Fellow in Economic Studies, Brookings Institution 2013 – 2015 Director, Initiatives on Value and Innovation in Health Care, Brookings Institution 2007 – 2013 Director, Engelberg Center for Health Care Reform, Brookings Institution 2006 – 2007 Visiting Senior Fellow, AEI-Brookings Joint Center for Regulatory Studies, American Enterprise Institute and the Brookings Institution 2004 – 2006 Administrator, Centers for Medicare and Medicaid Services, U.S. Department of Health and Human Services 2002 – 2004 Commissioner, U. S. Food and Drug Administration 2001 – 2002 Member, Council of Economic Advisers, and Senior Director for Health Care Policy, White House
    [Show full text]
  • May 13 Federal Update
    Congressional and Federal Agency Responses and Opportunities Regarding the COVID-19 Outbreak Lewis-Burke Associates LLC May 13, 2020 Table of Contents Introduction ................................................................................................................................................. 3 Congressional and Federal Updates ............................................................................................................. 3 Update: Democrats Unveil Proposed $3 Trillion Response Package ........................................................ 3 Update: House, Senate Committees Hold Hearings on COVID-19 Response ........................................... 9 Federal Guidance Related to Research and Higher Education ................................................................... 10 Office of Management and Budget (OMB) ............................................................................................ 10 Update: Department of Education (ED) ................................................................................................. 12 National Institutes of HealtH (NIH) ......................................................................................................... 15 Department of HealtH and Human Services (HHS) ................................................................................. 16 Centers for Medicare and Medicaid Services (CMS) .............................................................................. 16 Food and Drug Administration (FDA) ....................................................................................................
    [Show full text]
  • IHP News 559 : “Public Enemy Number One”
    IHP news 559 : “Public enemy number one” ( 14 February 2020) The weekly International Health Policies (IHP) newsletter is an initiative of the Health Policy unit at the Institute of Tropical Medicine in Antwerp, Belgium. Dear Colleagues, I know, I know, it’s Valentine today, so I probably shouldn’t talk about the eerily sounding “Covid- 19” in this short intro, let alone about the even more dreaded “P word” but WHO and dr. Tedros were clearly in no mood for Valentine earlier this week, when describing the virus as “a global threat, potentially worse than terrorism”. “The world must wake up and consider this enemy virus as public enemy number one,” Tedros said. With world media and public opinion going berserk all around the world for a few weeks now, I think that shouldn’t be too much of a problem. The other part of his message, however, that it’s about "solidarity, solidarity and solidarity", might prove much harder in the weeks and months to come, given how Sapiens is wired. When thinking of pandemics, in this visual culture of ours, we probably all have (subconsciously or not) a particular movie in mind when considering some of the most dire scenarios. For some of you, that might be “Contagion”, for me, it’s no doubt “Twelve Monkeys” (1995), with among others, Bruce Willis, a stunning Madeleine Stowe and a young Brad Pitt. Back in the innocent ‘90s, it all felt a bit surreal, even the obligatory rogue scientist popping up towards the end. But what a great movie! Now in the year 2020, with the scary ongoing public health experiment (aka ‘the coronavirus cruise ship quarantines’), occasionally I get the feeling that “Twelve Monkeys” is being mixed up with “the Poseidon Adventure” .
    [Show full text]
  • Corman-Drosten Review Report
    Healthy Gallatin From: Owen Giddings <[email protected]> Sent: Wednesday, February 3, 2021 3:30 PM To: BOHPublicComment Subject: Vaccination rates Categories: NonAgendaPC Could the Health Board please speak in concrete terms to why Gallatin County is lagging significantly behind all of Montana's other large cities in vaccination rates, per the Montana Covid dashboard? First shots administered: as of 2/3: Missoula Count (Missoula): 12.9% vaccinated Lewis and Clark County (Helena): 14.4% vaccinated Yellowstone County (Billings): 14.6% vaccinated Cascade County (Great falls): 12.8% vaccinated Gallatin County: 8.1% vaccinated Silver Bow County (Butte): 17.7% vaccinated 1 Healthy Gallatin From: Administrator <[email protected]> Sent: Wednesday, February 3, 2021 1:29 PM To: BOHPublicComment Subject: mask mandate Categories: NonAgendaPC BOH members and staff, I continue to be dismayed at the lack of enforcement of the mask order in commercial establishment in Bozeman. The BOH inclusion of an exemption for medical reasons provides an illogical loophole big enough for the Queen Mary. Nobody with an actual respiratory health issue is going to be maskless out in public and run the risk of encountering some asymptomatic anti‐masker. Responsible businesses include an option for curbside service for those who don’t want to comply with the mask requirement. The choice to enter a business includes the responsibility to adhere to the safety policies of that business. Smoking or going naked are not tolerated by businesses, going maskless shouldn’t be either. Employees maybe exposed to scores or hundreds of customers each day. Gallatin County’s positivity rate all but insures that the typical service industry employee will encounter people who are infected.
    [Show full text]
  • The Diocese of Southeast Florida's Reopening
    On Being Faithful Guidelines for a Shared Discernment on the Way Ahead in this Season of COVID-19 But now thus says the Lord, he who created you, O Jacob, he who formed you, O Israel: Do not fear, for I have redeemed you; I have called you by name, you are mine. For I am the Lord your God, the Holy One of Israel, your Savior. Do not remember the former things, or consider the things of old. I am about to do a new thing; now it springs forth, do you not perceive it? I will make a way in the wilderness and rivers in the desert. [Isaiah 43:1,3,18-19] Preface Little did we know when the forty days of Lent began, that we would end the season in quarantine, either self-imposed, as if in a kind of strict Lenten fast, or enforced by guidelines promoted to protect public health and safety. From the forty (Latin: quaranta) days of Lent we have passed through the remembrance of Christ’s saving death and glorious resurrection into the fifty days of the Easter season, sure that Jesus Christ is risen, but still wondering when it might be safe for us to emerge from our own ‘tombs’ into the light of a new day. The new day has come, but we would do well to acknowledge that it is of a different kind and order, and one which no longer holds any certainty in this COVID-19 world. In this unwelcome season of the COVID-19 virus, we find ourselves living through a period of volatility, uncertainty, complexity, and ambiguity, or, for short, a VUCA season.
    [Show full text]